







Opinion

The use of aerosolized -Adrenergic agonist therapy after lung transplantation in pediatric age

Giorgia Grutter^{1*} and Zaccaria Ricci²


¹Department of Cardiology and Cardiac Surgery, Heart Failure, Mechanical Circulating Support and Thoracic Transplant Unit ,Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

²Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

Received: 04 May, 2020 Accepted: 27 June, 2020 Published: 29 June, 2020

*Corresponding author: Giorgia Grutter, Department of Cardiology and Cardiac Surgery, Pediatric Cardiac Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, Tel: +39 0668592449; Fax: +39 0668592607; E-mail: giorgia.grutter@opbg.net

https://www.peertechz.com



It is my opinion the use of aeresolized -adrenergic agonist such as salbutamol may be helpfull not only to reduced the early mortality but also the chronic allograft dysfunction after lung transplantation in children The reduction of pulmonary edema could be prevent the induction of Obstructive Bronchiolites Syndrome (less pneumonia and viral infections etc) such as the primary graft dysfunction.As we know by international literature Lung transplantation continues to suffer from lessthan-ideal long-term outcomes, even in pediatric patients. Pediatric age recipients post-transplant survival is better for patients aged <12 years than for patients aged 12-17 years (median survival of 6.5-8.2 and 4.8 years, respectively). Reflecting the relatively high perioperative and early mortality after lung transplantation there is a large discrepancy between overall and 1-year conditional survival for lung transplant recipients. Conditional median survival is 9.7-11.2 years for patients aged 0-11 years and 7.7 years for patients aged 12-17 years [1,2]. the use of aerosolized-adrenergic agonist therapy reduces pulmonary edema following lung surgery. Several experimental studies have provided convincing evidence that 2-adrenergic agonist therapy can accelerate the removal of alveolar edema fluid in both normal and injured lungs, primarily by a cyclic adenosine monophosphate-mediated increase in the vectorial transport of sodium and chloride across both alveolar epithelial type I and type II cells [3,4]. These findings provide striking evidence that short-term use of aerosolized 2-agonists can enhance the resolution of pulmonary edema, even when administered to nonintubated patients.

We used successfully aereosolized salbutamol in a child 3 ys old, a female with a complex congenital heart disesease undergone several cardiac operations. After Mechanical assistance support she undergone iHeart and Lung transplantation, aftre 2 weeks she had numerous complications such as tracheostomy, increase of panel reactive antibodies (PRA) and and importantant reduction of lung function . Maintenance She was since tranplantation treated iwith inibithor of calcineurine (FK56) i.v, steroids i.v and oral mycofolanate mofetil. She also due elevated PRA was underwent three cycles of plasmapheris, wassociated aereoslized salbulatomol three once/day (0,15 mg/kg each cycle).

Now the child is discharged with an optimal lung function (removed tracheostomy) and she is at home

Discussion

Lung or heart lung transplantation in child is a very complex "life strategy", infections, pulmonary lung dysfunction and rejection are the most causes of death. The use of aeresolized salbutamol help lung ventilation.

References

- 1. Lancaster TS, Eghtesady P (2018) State of the Art in Pediatric 30: 166-174. Link: Lung Transplantation. Semin Thoracic Surg https://bit.ly/3i5AHtD
- 2. Benden C (2017) Pediatric lung transplantation. J Thorac Dis 9. Link: https://bit.ly/2Ziii4j

3. Matthay MA, Calfee CS (2008) Aerosolized -Adrenergic Agonist Therapy Reduces Pulmonary Edema Following Lung Surgery. Chest 133.

Peertechz® Publications

4. Cai Z, Lin Y, Liang J (2020) Efficacy of salbutamol in the treatment of infants with bronchiolitis A meta-analysis of 13 studies. Medicine 99: e18657. Link: https://bit.ly/3dxGCUU

Discover a bigger Impact and Visibility of your article publication with **Peertechz Publications**

Highlights

- Signatory publisher of ORCID
- Signatory Publisher of DORA (San Francisco Declaration on Research Assessment)
- Articles archived in worlds' renowned service providers such as Portico, CNKI, AGRIS, TDNet, Base (Bielefeld University Library), CrossRef, Scilit, J-Gate etc.
- Journals indexed in ICMJE, SHERPA/ROMEO, Google Scholar etc.
- OAI-PMH (Open Archives Initiative Protocol for Metadata Harvesting)
- Dedicated Editorial Board for every journal
- Accurate and rapid peer-review process
- Increased citations of published articles through promotions
- Reduced timeline for article publication

Submit your articles and experience a new surge in publication services (https://www.peertechz.com/submission).

Peertechz journals wishes everlasting success in your every endeavours.

Copyright: © 2020 Grutter G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.